Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer
Objectives:We tested cytoplasmic HuR (cHuR) as a predictive marker for response to chemotherapy by examining tumor samples from the international European Study Group of Pancreatic Cancer-3 trial, in which patients with resected pancreatic ductal adenocarcinoma (PDA) received either gemcitabine (GEM
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018/02/01
|
| In: |
Annals of surgery
Year: 2018, Volume: 267, Issue: 2, Pages: 364-369 |
| ISSN: | 1528-1140 |
| DOI: | 10.1097/SLA.0000000000002088 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1097/SLA.0000000000002088
|
| Author Notes: | Talar Tatarian, Wei Jiang, Benjamin Leiby, Amanda Grigoli, Masaya Jimbo, Nooreen Dabbish, John Neoptolemos, William Greenhalf, Eithne Costello, Paula Ghaneh, Christopher Halloran, Daniel Palmer, Markus Buchler, Charles Yeo, Jordan Winter, Jonathan Brody |
| Summary: | Objectives:We tested cytoplasmic HuR (cHuR) as a predictive marker for response to chemotherapy by examining tumor samples from the international European Study Group of Pancreatic Cancer-3 trial, in which patients with resected pancreatic ductal adenocarcinoma (PDA) received either gemcitabine (GEM |
|---|---|
| Item Description: | Gesehen am 09.05.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1528-1140 |
| DOI: | 10.1097/SLA.0000000000002088 |